ROIVANT SCIENCES LTD. Accounts Payable
ROIVANT SCIENCES LTD. (ROIV) had Accounts Payable of $25.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $25.08M.
- 2026-03-31: Accounts Payable, Current $18.00M.
- 2025-12-31: Accounts Payable, Current $13.29M.
- 2025-09-30: Accounts Payable, Current $15.06M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $25.08M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $18.00M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $13.29M 10-Q · filed 2026-02-06 | |
| 2025-09-30 | $15.06M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $11.55M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $23.69M 10-K · filed 2026-05-20 | |
| 2024-12-31 | $23.71M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $25.13M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $27.74M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $14.03M 10-K · filed 2025-05-29 | $53.23M 10-K · filed 2024-05-30 |
| 2023-12-31 | $35.23M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $44.12M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $50.03M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $37.83M 10-K · filed 2024-05-30 | |
| 2022-12-31 | $48.00M 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $41.36M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $161.30M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $34.58M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $24.36M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $77.16M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $15.01M 10-Q · filed 2021-09-21 | |
| 2021-03-31 | $20.55M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |